Status:
ACTIVE_NOT_RECRUITING
EndeavorRx® Prospective Product Registry ("Expedition EndeavorRx")
Lead Sponsor:
Akili Interactive Labs, Inc.
Conditions:
ADHD
Eligibility:
All Genders
Brief Summary
The EndeavorRx Prospective Product Registry aims to collect real world data from participants receiving the digital therapeutic, EndeavorRx, under conditions of routine clinical practice.
Detailed Description
The objectives of this registry are to describe clinical and demographic characteristics, prescribing patterns, treatment patterns, and outcomes in participants treated with EndeavorRx in a real-world...
Eligibility Criteria
Inclusion
- Are prescribed EndeavorRx by their healthcare provider as part of routine clinical practice
- Provide informed consent/assent to participate in the registry
Exclusion
- N/A
Key Trial Info
Start Date :
June 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2025
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT05991167
Start Date
June 1 2022
End Date
December 31 2025
Last Update
June 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Akili Interactive Labs, Inc.
Boston, Massachusetts, United States, 02110